A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
Price : $35 *
At a glance
- Drugs Daprodustat (Primary) ; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 31 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.